Edgar Ben-Josef, MD

Radiation Oncology
Accepting new patients
Sees patients age 18 and up
Penn Radiation Oncology Perelman - 2nd Floor
Make an appointmentCall 800-789-7366
Penn Medicine Provider

About me

  • Vice Chair, Translational Research, Radiation Oncology
  • Professor of Radiation Oncology at the Hospital of the University of Pennsylvania

My education and training

  • Medical School: Hebrew University Hadassah Medical Center
  • Residency: Beilinson Medical Center
  • Residency: Harper Hospital

Spoken languages

English
English
עברית
Hebrew

Reviews

Average Rating

59 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
August 2026
caring and answered all questions
Anonymous
July 2026
he did exactly what he said he would do!
Anonymous
June 2026
he answered all our questions and made us feel very comfortable with the treatment we are going to receive.
Anonymous
June 2026
amazing doctor. i appreciated all of his efforts to help guide be to make the best decisions. very thorough. well spoken.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

PRIMARY LOCATION
800-789-7366
Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Ben-Josef is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Uri Amnit et al. FLASH Proton Radiotherapy Preserves Ocular Structure and Function Without Compromising Antitumor Efficacy , Int J Radiat Oncol Biol Phys , S0360-3016(26)04233-1: 2026

Avinash Ramkissoon, Uri Amit, Miguel Perez-Guillermo Cuev, Kevin Risolo, Cecilia Jiang, Karishma Khullar, Edgar Ben-Josef Impact of Gross Tumor Volume (GTV) and Effective Uniform Dose (EUD) on Clinical Outcomes after SBRT for Hepatocellular Carcinoma (HCC) , Annual Meeting Proceedings ASTRO 2026: 2026

Andy Minn, Yuwei Qi, Taewon Yoon, Uri Amit, Brian Kim, Jacob Shabason, Olivia Oldridge, Jesse Donovan, Alexei Korennykh, Erica Carpenter, Thomas Karasic, and Edgar Ben-Josef Radiation Activates RNASEL to Enhance Immunotherapy by Disrupting a Circular RNA Checkpoint for Immunotransmission , In review: Cancer Cell: 2026

Edgar Ben-Josef 1, Andrew M Lowy 2 A Novel Adjuvant Chemoradiotherapy/Immunotherapy for Resected Biliary Cancer , JAMA Oncol: 2025

Uri Amit 1 2, James M Metz 2, John P Plastaras 2, Rohi Gheewala 2, Ursina Teitelbaum 3, Nevena Damjanov 3, Charles Vollmer 4, Charles J Schneider 3, Major Kenneth Lee 4th 4, Mark O'Hara 3, Kim Reiss-Binder 3, Erica L Carpenter 3, Thomas B Karasic 3, Andre Konski 2, E Paul Wileyto 5, Edgar Ben-Josef 2 A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer , Cancer, 131(12): 2025,e35936

Grace Lee 1, Bailey Nelson 2, Julie Koenig 1, John P Plastaras 3, James M Metz 3, Beow Y Yeap 4, Yongbin Zhang 2, Lorraine C Drapek 1, Christian Baglini 4, David P Ryan 4, Aparna R Parikh 4, Jill N Allen 4, Jeffrey W Clark 4, Lawrence S Blaszkowsky 4, Edgar Ben-Josef 3, Theodore S Hong 1, Jordan R Kharofa 5, Jennifer Y Wo 6 Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials , Int J Radiat Oncol Biol Phys, 122(1): 2025

Timothy J Brown 1, Uri Amit 2, Rohi Gheewala 2, Edgar Ben-Josef 2, Thomas B Karasic 2 Evaluating the Safety and Efficacy of Adding Liver-Directed Radiation Therapy to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Analysis , Am J Clin Oncol, 10.1097/COC.0000000000001214: 2025

Steven Joel Feigenberg 1, Francesca Costabile 1, Ceylan Tanes 2, Kyle Bittinger 2, Roderick O'Connor 3, Divyansh Agarwal 4, Giorgos Skoufos 5, Silavano Salaris 6, Artemis Hatzigeorgiou 5, Nektarios Kostopoulos 1, Shane Lloyd 7, Cole Friedes 1, Lisha Chen 1, Nikhil Yegya-Raman 1, Keith Cengel 1, William Levin 1, Bakir Valentić 3, Tyler Quarton 8, Alexander A Shestov 9, Abigail Berman 10, Jeffrey Bradley 1, Amit Maity 7, Costantinos Koumenis 1, Edgar Ben-Josef 1, Andrea Facciabene 11 12 Enhancing outcomes in medically inoperable early-stage NSCLC with gut-targeted antibiotics and stereotactic body radiotherapy: results from a randomized pilot study , J Immunother Cancer, 13(7): 2025

Andrea Facciabene et al. Gut-targeted antibiotic modulation enhances radiotherapy in NSCLC: new epigenetic and dendritic cell functional correlates from a randomized pilot trial. , SITC 40th Anniversary Annual Meeting: 2025

Uri Amit MD MPH PhD 1, Misra Shagun MD2, John P Plastaras MD PhD1, James M Metz MD1, Thomas B Karasic MD3, Maryanne J Lubas MD4 and Edgar Ben-Josef MD1 Clinical Outcomes and Risk Stratification in Unresectable Biliary Tract Cancers Undergoing Radiation Therapy , ASTRO 2024 Annual Meeting, 19(1): 2024